Pattern of mismatch repair proteins in colorectal cancer patients in tertiary cancer center.

Authors

null

Ajinkya Shantaram Kale Sr.

Tata Memorial Center, Mumbai, Maharashtra, India

Ajinkya Shantaram Kale Sr., Avanish Saklani

Organizations

Tata Memorial Center, Mumbai, Maharashtra, India, Tata Memorial Hospital, Mumbai, India

Research Funding

No funding received
None.

Background: Prevalence of MSI high in colorectal cancer patients in India has been debated in previous literature. Microsatellite instability pathway is one of the major pathways in carcinogenesis of colorectal carcinoma. MSI status has paramount significance in therapeutic and prognostic aspects of colorectal cancer management. MSI status can be evaluated by presence or absence of mismatch repair proteins. Aims & objectives: we aimed to determine the prevalence of MSI high in colorectal carcinoma and pattern of mismatch repair proteins. Methods: This was retrospective study which included consecutively operated colorectal carcinoma patients from 01 may 2022 to 31 December 2022 in our institute. Immunohistochemistry with four mismatch repair (MMR) proteins; MLH1, MSH2, MSH6, and PMS2 was performed. Correlation with various clinical and histopathological features was done. Results: total 296 colorectal carcinoma patients were included in our study. Fourty one (13.85%) patients were MSI high. Most common pattern of MMR protein expression loss was dual loss of MLH1 and PMS2 (n=18). Most common single protein loss was PMS2 (n=22). Most common location of tumor in MSI high patients was the right colon. (n=20). Out of 153 carcinoma rectum patients only five patients were MSI high. Conclusions: The study shows that prevalence of MSI high is more common in right colon cancer. Prevalence of MSI high is very low in carcinoma rectum. We discuss and compare our results with previous studies.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session B

Track

Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies

Sub Track

Diagnostics

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 40)

DOI

10.1200/GO.2023.9.Supplement_1.40

Abstract #

40

Poster Bd #

B7

Abstract Disclosures